Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
NLY01 in Early-stage Parkinson's Disease
NCT04154072Phase 2Completed
- Sponsor
- Neuraly
- Start
- Feb 2020
- Primary completion
- Feb 2023
- Modality
- Polymer-based Nanoparticles, Modified Peptides, Native Peptides
- Countries
- 2
01
Overview
A Phase 2 trial of pegsebrenatide in Parkinson's disease (PD), sponsored by Neuraly. Started Feb 2020; status: completed.
02
Drugs
pegsebrenatide
03
Conditions
Parkinson's disease (PD)
Beyond the preview
Go deeper on NCT04154072.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04154072.